Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on ...

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

Strides Pharma Science Ltd (BOM:532531) reports a robust quarter with 13.3% revenue growth and significant debt reduction, while navigating challenges in regulated markets.

Revenue increased 15% YoY at ₹1,153.7 crore from ₹1,005.8 crore in Q3 FY24, marking a consistent business growth.

Strides Pharma Science in its consolidated financial results for the quarter Q3FY25 ended December 31, 2024 reported revenues of Rs. 1,153.7 crore with a growth 14.6% YoY in Q3FY25. The PAT stood at ...

Bangalore: Strides Pharma Science Limited has announced that the Company has received an ESG score of 76/100 and CSA score of ...

Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global’s Corporate Sustainability Assessment: Our Bureau, Bengaluru Wednesday, January 22, 2025, 13:40 Hrs [ ...

Strides Pharma Science Ltd., incorporated in the year 1990 ... after tax of Rs 89.09 Crore in latest quarter.The company’s top management includes Mr.Arun Kumar, Mr.Badree Komandur, Mr.Aditya Kumar, ...

The promotor/promotors of Strides Pharma Science Ltd are Arun Kumar, Manjula Ramamurthy, Homi Rustam Khusrokhan, Badree Komandur, Kausalya Santhanam, Subir Chakraborty, Ameet Hariani, Aditya Kumar.

Strides Pharma Science Limited is a global pharmaceutical ... as Independent Director of the Company effective February 1 2025.Change in designation of Mr. Arun Kumar (DIN: 00084845) from Executive ...